Business Context and Reporting Period
Company: BioCardia, Inc. (BCDA)
Filing Type: Form 8-K (Current Report)
Date of Report: April 15, 2025
Primary Event: Regulation FD Disclosure regarding the CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial.
Key Financial Metrics
This filing is a current report regarding a clinical trial update and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity is not provided in this document.
Material Changes
The filing reports a material development in the company's clinical operations rather than financial performance:
- Clinical Trial Status: The independent Data Safety Monitoring Board (DSMB) conducted a planned review of 30-day safety data from the roll-in 20 million cell dosing cohort.
- DSMB Recommendation: The board recommended that the study continue as designed.
- Safety Findings: No treatment emergent major adverse cardiac events were observed. There was no clinical evidence of immune reactions to the allogeneic cells implanted.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) confirming the positive safety review. No specific financial guidance or forward-looking revenue projections are included in this text.
Risks and Contingencies: While the immediate safety review was positive, the filing does not detail long-term risks or contingencies beyond the standard nature of clinical trials.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for additional context on the trial design.
- Review the company's most recent 10-Q or 10-K filing for current cash runway and burn rate, as this 8-K contains no financial data.
- Monitor future DSMB reports for the next scheduled safety review milestones.
- Confirm the timeline for the next phase of the CardiALLO trial based on the "continue as designed" recommendation.